Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ductal Breast Carcinoma in Situ: early-phase trial registry
2 of 12 indexed Ductal Breast Carcinoma in Situ trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 2 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Ductal Breast Carcinoma in Situ: 12 US clinical trials tracked, 2 recruiting.
Ductal Breast Carcinoma in Situ is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition ductal-breast-carcinoma-in-situ
OPEN 2 | RECR 17% | LATE 1 | EARLY 7 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Ductal Breast Carcinoma in Situ lists 2 open slots (17% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ductal Breast Carcinoma in Situ on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ductal Breast Carcinoma in Situ is recruiting below its size-band peers.
2 of 12 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ductal Breast Carcinoma in Situ research.
M.D. Anderson Cancer Center accounts for 3 of 12 trials (25%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Ductal Breast Carcinoma in Situ enrolment sits around 144 participants.
Median target enrolment is 144 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.
-
Ductal Breast Carcinoma in Situ research is mostly interventional.
12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
University of Utah
NCT06961955
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Stanford University
NCT03909282
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
ECOG-ACRIN Cancer Research Group
NCT02352883
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01266642
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
M.D. Anderson Cancer Center
NCT01245712
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
Northwestern University
NCT04009044
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
Alliance for Clinical Trials in Oncology
NCT01905046
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
M.D. Anderson Cancer Center
NCT03546972
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
Ohio State University Comprehensive Cancer Center
NCT04537312
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
Rutgers, The State University of New Jersey
NCT02526498
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT01869764
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT02150525
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ductal Breast Carcinoma in Situ records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ductal Breast Carcinoma in Situ trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ductal Breast Carcinoma in Situ page
12 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Ductal Breast Carcinoma in Situ trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Ductal Breast Carcinoma in Situ trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ductal Breast Carcinoma in Situ condition card totals 12 registered trials; most-linked intervention placebo; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.